Krcmery vladimir



Antibiotic resistance in 
antibiotic free environment

Antibiotic resistance in the absence of 
An association between antibiotic use and the development of clinical 
resisitance has been clearly documented in several cases
 Use of macrolides and resistance in S. pyogenes Use of penicillins and resistance S. pneumoniae Use of floroquinolones and resistance in Enterobacteriacea and P. aeruginosa Use of third-generation cephalosporins and resistance in Enterobacteriacea Use of carbapenems and resistance in P. aeruginosa Use of linezolid and resistance in E. faecium
Reversal of antibiotic resisitance following antibiotic-restriction 
policies has been documented in some cases
 Decrease of macrolide resistance in S. pyogenes after restriction in Finland Decrease of penicillins resisitance in S. pneumoniae after restriction in 
Hungary, Iceland, France
Pallecchi et al. Anti. Infect. Ther. 6(5):725-732 (2008)

Antibiotic resistance in the absence 
of antimicrobial use
 High rates of acquired antibiotic resistance have been 
detected among commensal bacteria isolated from humans and wild animals not subjected to significant antibiotic exposure and living in remote areas of the planet
 This observations underscore the mechanisms involved 
in the emergence and spread of antibiotic resistance 
 Better understanding of this mechanisms is crucial to 
improve strategies for antibioti-resistance control

Evidence for acquired under conditions of low 
or minimal antibiotic exposure
 The only available bacterial collection predating the antibiotic era is 
the Murray collection, including clinical isolates of Enterobacteriacae from widely separated areas
 collected during during 1917-1954
 In these isolates the presence of acquired resistance traits was
found to be negligible
 This observation strongly emphasized the role of antibiotic use in 
promoting dissemination of acquired resistance among pathogenic bacteria
Hughes and Datta, Nature 302:725-726 (1983)

Studies on antibiotic resistance in commensal 
bacteria from humans living in remote settings
 The first studies was conducted in the 1960s in an 
isolated community of Kalahari bushmen in South Africa, which was free of drugs and had been in contact with other humans for a period of approximately 10 years
 In that community fecal carriage of enteric bacteria with 
acquired resistance traits was found to be low overall, and was limited to ampicillin resistance in E. coli 
Mare IJ, Nature 220:1046-1047 (1968) 

Summary of studies on acquired resistance in 
commensal enteric bacteria from remote human 
populations with low or minimal antibiotic exposure
Approximate 
Hughes et al.
Mare et al.
Wakson et al.
Grenet et al.
Bartoloni et al.
Sladeckova et al.
 Nepalese village with very low 
access to allopathic medicines
 Investigation on the fecal carriege of 
antibiotic-resistant lactose-fermenting enterobacteria from healthy individuals 
 Resistance: amoxicillin, tetracycline, 
trimethoprim-sulfamethoxazole, chloramphenicol, much lower quinolones
Walson et al. J.Infect. Dis. 184:1163-1169 (2001)
Three traditional communities of Wayampis Amerindians, where exchanges with the exterior were limited and antibiotic consumption was moderate overall
Resistance pattern similar to that found in Nepal
Three individuals from this community were found to carry commensal E.coli resistant to expanded-spectrum cephalosporins due producing of the TEM-52 extended spectrum ß –lactamase (ESBL)
Resistant bacteria could be introduced into the community from antibiotic-exposed settings (e.g., through villagers that had been previously hospitalized)
Grenet et al. Emerg. Infect. Dis. 10:1150-1153 (2004)
Bolivian Chaco region
To date, most remote human communities investigated for carriage of antibiotic-resistant bacteria are two Amerindian communities located in the Bolivian Chaco region and the Peruvian Alto Amazonas district
High rates of fecal carriage of E.coli resistant to tetracycline, ampicillin, trimethoprim-sulfamethoxazole and chloramphenicol were detected in both communities
No resistance was observed for quinolones
Molecular characterization of resistant isolates from this area revealed a considerable variety of acquired resistance genes, entirely alike those encountered in resistant isolates from antibiotic-exposed settings in the same geographical areas
Bartoloni et al. J. Infect. Dis. 189:1291-1294 (2004)
 We tested 182 HIV 
negative patients from Mapuordit in South Sudan
 105 isolates – most frequently were 
Enterobacteriaceae, S. aureus, Moraxella catharralis, H. influezae,S. pyogenes 
 All 105 isolates were 100% sensitive 
to all antibiotics 
Sladeckova et al. Journal of infection, 53 (4):291-292 (2005)
 We carried Cambodian children 
before of treatment with HAART
 High colonization with MR-GNB 
(e.g. ceftazidime-resistant) Enterobacter spp. and Klebsiella pneumoniae in children who were antibiotic and HAART-naive 
 Colonization GPB - S. pyogenes
Shahum, Krcmery et al. Journal of Antimicrobial Chemotherpy, 60 (1):194-197
Reason for spread of MDR bacteria 
from SE Asia
 Not developing countries, any 
move , many height level hospitals
 Overproduction of generic 
 Exposition fake antibiotics with 
less antibiotic (low doses promote resistance)
 Huge concentrated poplulation 
(Indonesia, India, China) on a squere of SE Asia – 10 % OF WS
 Diarrheic regions whit 
Emergence of a new antibiotic resistance mechanism 
in India, Pakistan, and the UK: a molecular, 
biological, and epidemiological study 
 Identification of 44 isolates with NDM-1 in Chennai, 26 in Haryana, 
37 in the UK, and 73 in other sites in India and Pakistan
 NDM-1 was mostly found among Escherichia coli (36) and Klebsiella 
pneumoniae (111), which were highly resistant to all antibiotics except to tigecycline and colistin
 Most isolates carried the NDM-1 gene on plasmids: those from UK 
and Chennai were readily transferable whereas those from Haryanawere not conjugative. Many of the UK NDM-1 positive patients had traveled to India or Pakistan within the past year, or had links with these countries. 
Kumarasamy et al. The Lancet Infectious Diseases,10 (9):597 – 602 (2010)
Carbapenem resistance in E. coli from Australia due to metallo-beta-lactamase 
NDM-1
 Emergence of MBL NDM-1 in Australia after its recent identification in India and 
UK, in an E. coli isolate accumulating emerging broad-spectrum resistance determinants, including the ESBL CTX-M-15 and two 16S RNA methylases
Poirel et al., ICAAC, 2010
Dissemination of NDM-1-producing Enterobacteriaceae in India
 A new metallo-ß-lactamase, NDM-1 was identified in a K. pneumoniae (KPN) from 
a Swedish patient of Indian origin
 SENTRY program (2006-2007) – occurence and characterization of NDM-1-
producing strains from India
 15 (1%; 6 E. coli, 6 KPN and 3 E. cloaceae) isolates from New Delhi (2 sites), 
Mumbai and Pune carried blaNDM-1 
 All isolates were resistant to penicillins, cephalosporins and aminoglycosides, and 
susceptibility only to tigecycline and polymyxin B (two isolates were resistant)
Deshpande et al. , ICAAC, 2010
Recognition of NDM-1 AMONG Enterobacteriaceae in the United states
 This is the first report of bla NDM in the United states and of metallo-beta –
lactamase carriage among Enterobacteriacae in the US 
 These isolates are resistant to nearly all available therapeutic agents
Limbago et al., ICAAC, 2010
 Antimicrobial resistance and Extended-spectrum ß-lactamase 
(ESBL)-producing clinical isolates from urinary tract infections in Rwanda, East-Africa
 The findings of the present study reveal a significant icrase of resistance 
to various groups of antimicrobial drugs and prevalence of ESBL producers is first described among UTI pathogens
Muvunyi, ICAAC, 2010
 Emergence of metallo-ß-lactamase NDM-1 PRODUCING Klebsiella 
pneumoniae in Kenya
 Emergence of MBL NDM-1 in Africa, after the recent identification of 
NDM-1 producers in India and UK
 Worringly the K. pneumoniae isolates studied here accumulated many 
threatening mechanisms of resistance to antibiotics
Poirel et al., ICAAC, 2010
 The characteristic of mettallo-ß-lactamase producing E. coli isolates 
in Canada from a patient with recent travel to India
 This is the firs report of E.coli ST101 with NDM-1 metalo-
carbapenemase and Ctx-M15 ESBL from Canada
Peirano, ICAAC, 2010
Carbapenem-resistant Klebsiella pneumoniae (CRKP) in post-acute 
care facilities (PACF) IN Israel: A national intervention
 There is a major burden of CRKP carriage in PACF
Ben-David et al., ICAAC, 2010
Multidrug-resistant Enterobacteriaceae including NDM-1 metallo-ß-
lactamase producers are predominant paththogens of HCAIs in an 
Indian teaching hospital
 Carbapenems were in little use but selection pressure exerted by other classes 
was sufficient to select carbapenemsmase due to co-selection suggesting role of single plasmid carrying multiple resistnace genes
Sarma Male et al., ICAAC, 2010
How to reduce the spread of resistance?
How to reduce the spread of resistance ?
Hospital antibiotic policy
How to reduce the spread of resistance ?
Internal cooperation and meetings
How to reduce the spread of resistance?
Improving health care infrastructure
Burundi Celebrity ATB-R free Environment
In Sub-Sahara Africa and Latin 
America ATB-R in remote settings is minimal
In South and SE Asia multiresistant strains are emergence and they spread all over the world from e.g. Taiwan, Hong Kong, India (e.g. PVDM-1, PRP, ERY-R S. pyogenes)
Selective pressure generated by the use of antibiotics in clinical, veterinary, husbandry and agricultural practices is considered the major factor responsible for the emergence and spread of antibiotic-resistant bacteria since the beginning of the antibiotic era
Acquired resistance traits can also be found in bacteria isolates from humans not subjected to significant antibiotic exposure and living in remote areas of the planet
Thanks for your attention!
Source: http://www.krankenhaus-hygiene.at/images/vortrag_krcmery.pdf
   F-MELT series, Issue2, February 2011 Formulating Taste Masked  and High Quality ODT of  Poorly Water Soluble Drugs  In this paper, we present case studies with taste masking technology and application of wet granulation  technologies to develop ODTs of Loratadine, a water insoluble drug, and Famotidine, a slightly water 
  
   Philips SMART Biphasic therapy Application note Philips SMART Biphasic therapy  Since Philips introduced the first biphasic waveform for an external defibrillator in 1996, biphasic therapy has gained acceptance and is now recognized as the standard of care. However, the various defibrillator manufacturers recommend a wide range of energy (joules) dosages. This is because defibrillator manufacturers have created distinct biphasic waveform "formulations." So each manufacturer recommends energy doses appropriate for their shock formulation. While energy (joules) remains entrenched in defibrillator vocabulary as a descriptor of shock strength, current (amperes) has been shown to be a better predictor. For meaningful shock strength comparisons of biphasic waveforms, it's necessary to look beyond energy levels and compare the current delivered to the patient.